GLENEAGLES GLOBAL HEALTH CITY LAUNCHES DEDICATED HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) CENTRE FOR ADVANCED ABDOMINAL CANCERS
~ Dr. J Radhakrishnan, Additional Chief Secretary & Commissioner, Greater Chennai Corporation inaugurated South India’s First Dedicated Centre for advanced abdominal cancer ~
Chennai, 26th July 2023: Gleneagles Global Hospital (GGHC), a leading healthcare institution known for its excel lence in providing comprehensive medical services launched South India’s First Dedicated Hyperthermic Intrape ritoneal Chemotherapy (HIPEC) Centre for the Management of advanced abdominal cancers in Chennai today. D r. J Radhakrishnan, Additional Chief Secretary & Commissioner, Greater Chennai Corporation inaugurated the facility was launched in the presence of Dr. Alok Khullar, CEO, Gleneagles Global Health City, Chennai, and Prof Dr. Rajasundaram S, Director, Gleneagles Global Cancer Centre Head – Surgical Oncology.
Over 50% of ovarian cancer, 30-50% of stomach cancer, and 20% of colorectal cancer spread to the peritoneal su rface of the abdominal cavity. Patients with peritoneal surface malignancy have been treated with palliative che motherapy for years along with supportive care to increase the survival rate by 1-2 years. With an aggressive sur gical approach like Cytoreductive surgery and HIPEC, more than 50% of these patients survive for over 5 yea rs.
The HIPEC Centre launched is equipped with specialized facilities and a multidisciplinary team of healthcare pro fessionals, including surgical oncologists, medical oncologists, radiologists, nurses, and other support staff. The c enter will offer a holistic approach to patient care, providing support services such as counseling, nutritional gui dance, and pain management, and also contribute to research and advancements in the field, leading to improve d outcomes for patients in the long run.
Speaking on the occasion, Dr. J Radhakrishnan, Additional Chief Secretary & Commissioner, Greater Chennai Co rporation said, “It requires high levels of precision, advanced technologies and the latest infrastructure to treat intraperi toneal abdominal cancer. The newly launched HIPEC centre at Gleneagles Global Health City is a valuable addition to th e state’s healthcare infrastructure in providing advanced and high-quality cancer care and treatment.”
Speaking at the launch, Prof. Dr. S. Rajasundaram, Director – Gleneagles Global Cancer Centre & Head – Surgica l Oncology at Gleneagles Global Health City, Chennai, said, “While conventional chemotherapy circulates throughou t the body in the bloodstream, HIPEC delivers chemotherapy directly to the cancer cells within the peritoneum (the lining of the abdomen). This procedure increases the efficacy of the drug as the cells are subjected to higher doses of chemother apy. Before commencing with HIPEC, the patient undergoes complete cytoreductive surgery (CRS) where all macroscopic diseases from the abdominal cavity are surgically removed. We have performed over 100 successful HIPEC procedures in patients suffering from advanced abdominal cancer within the cavity.”
The cytoreductive surgery involves the resection of organs like the rectosigmoid, antrum of the stomach, and ga ll bladder. Following the CRS procedure, a heated, sterilized chemotherapy solution is delivered to the abdomen by a special dedicated HIPEC machine to penetrate and destroy the remaining cancer cells. The solution is heate d to the temperature of a warm bath approximately up to 41-42 degrees Celsius [between 105 and 109 F] for ap proximately 90 minutes. The solution is then drained from the abdomen, and the incision is closed.
Speaking at the launch, Dr. Alok Khullar, CEO, Gleneagles Global Health City, Chennai, and Mr. Anurag Yadav, CE O, IHH Healthcare India said, “ The establishment of a dedicated center for HIPEC indicates a commitment to providin g state-of-the-art care for patients with abdominal cancer. Dr. Rajasundaram and his team of experts are paving the way for best-in-class treatment for intraperitoneal abdominal cancer.”
About Gleneagles Global Health City, Chennai
Gleneagles Global Health City, the sprawling 14.5-acre facility located in Perumbakkam, Chennai, is the largest facility of Gleneagles Global Hospitals India. With 200 Licensed beds and accreditations from leading agencies, t he facility is Asia’s most trusted and leading Multi-Organ Transplant Centre. The hospital has undertaken several path-breaking Liver, Neuro, Heart, Lung and Kidney procedures. It is recognized by several national-level accre d iting agencies. World-class infrastructure, dedicated staff and a commitment for medical excellence are the USP s of this facility. The hospital has several achievements to its credit and continues to work on several pioneering procedures.
Gleneagles Global Hospitals has multi-super specialty hospitals in Bengaluru, Hyderabad, Chennai and Mumbai. The brand is the most preferred hospital group for multi-organ transplants in Asia region. The parent entity of Gl eneagles Global Hospitals is IHH Healthcare, a leading premium integrated healthcare provider with a network of 84 hospitals and more than 16,000 licensed beds. It is one of the largest healthcare groups in the world by mar ket capitalisation and is listed in the Main Market of Bursa Malaysia and Main Board of SGX-ST. IHH is a leading player in the home markets of Malaysia, Singapore, Turkey and India, and in their key growth markets of China and Hong Kong.
